Ceftaroline....


Anonymous

Guest
Shouldn't we be talking about this??????

Forest Laboratories’ (FRX) ceftaroline received a surprisingly unanimous backing Tuesday from an FDA advisory committee, boding well for final approval from the FDA.

The relatively smooth passage also suggests that concerns that the antibiotic might be tripped up by the ongoing debate around the evaluation of such products in the US were overstated. As such, after a pretty torrid time for antibiotic approvals in the US, other companies approaching the FDA with late stage antibiotics could well be taking comfort from ceftaroline’s progress so far.
 

Well ding dong what do you want to talk about? It can't touch us in terms of coverage. Learn your PI before you open your trap.... It will be an absolute non-player.......
 
Well ding dong what do you want to talk about? It can't touch us in terms of coverage. Learn your PI before you open your trap.... It will be an absolute non-player.......

Now how do you awesome Cubicin reps. figure this? The drug will cover gram +, and gram - bugs, including MRSA. Does anyone have to tell you how it will touch Cubicin in terms of coverage. And cSSTI infections are often polymicrobial, excluding cellulitis. Adding a 200+ dollar a day drug to another to cover gram - bugs, and maybe a third if anaerobes are present. Calculate that daily cost of therapy along with a double or triple drug regimen vs. a broad gram -, gram - + MRSA for the same polymicrobial infection, only adding for anaerobic coverage if needed at probably $100 dollar a day or less. Plus the fact that ceftaroline is a 5th gen Ceph. (a class that doctors are historically comfortable prescribing). Do you get it now. It will definitely be a player in the cSSTI market.
 
Good analysis. However, the big weasel in the wood pile is access. It is nearly impossible for me to get into my accounts anymore.
 
Now how do you awesome Cubicin reps. figure this? The drug will cover gram +, and gram - bugs, including MRSA. Does anyone have to tell you how it will touch Cubicin in terms of coverage. And cSSTI infections are often polymicrobial, excluding cellulitis. Adding a 200+ dollar a day drug to another to cover gram - bugs, and maybe a third if anaerobes are present. Calculate that daily cost of therapy along with a double or triple drug regimen vs. a broad gram -, gram - + MRSA for the same polymicrobial infection, only adding for anaerobic coverage if needed at probably $100 dollar a day or less. Plus the fact that ceftaroline is a 5th gen Ceph. (a class that doctors are historically comfortable prescribing). Do you get it now. It will definitely be a player in the cSSTI market.

5th generation my ass-its a ceph
 
Shouldn't we be talking about this??????

Forest Laboratories’ (FRX) ceftaroline received a surprisingly unanimous backing Tuesday from an FDA advisory committee, boding well for final approval from the FDA.

The relatively smooth passage also suggests that concerns that the antibiotic might be tripped up by the ongoing debate around the evaluation of such products in the US were overstated. As such, after a pretty torrid time for antibiotic approvals in the US, other companies approaching the FDA with late stage antibiotics could well be taking comfort from ceftaroline’s progress so far.

Since you launched Cubicin the market has changed. Forest is an unknown-if you were at ICAAC you saw a dump company with a dump booth. They have zero experience anywhere in the company and have promoted internally to fill positions.....if they impact you that is your fault. WIll they get business yes, it is a ceph and they are considered quite safe so they will be used. Outside oif that no big deal.
 
When you peel behind the first layer you realize how stupid the cubicin reps. really are who say things like "yeah, its a 5th gen. ceph. that will get business, and docs are comfortable with cephs., but no big deal, wont hurt cubicin". Keep telling yourself that everyone wants to use a 200+ day drug for resistant gram+ skin infection when there are other lower cost options in the market. You people must not get access to much market data.
 
Cubist? Cube tub. Is this a joke. A bunch of dumb jock in the company. Losers. The party is over Da da da. Yes, Cefaroline will end your jobs. Who would hire a Cube Rep?
 
Now how do you awesome Cubicin reps. figure this? The drug will cover gram +, and gram - bugs, including MRSA. Does anyone have to tell you how it will touch Cubicin in terms of coverage. And cSSTI infections are often polymicrobial, excluding cellulitis. Adding a 200+ dollar a day drug to another to cover gram - bugs, and maybe a third if anaerobes are present. Calculate that daily cost of therapy along with a double or triple drug regimen vs. a broad gram -, gram - + MRSA for the same polymicrobial infection, only adding for anaerobic coverage if needed at probably $100 dollar a day or less. Plus the fact that ceftaroline is a 5th gen Ceph. (a class that doctors are historically comfortable prescribing). Do you get it now. It will definitely be a player in the cSSTI market.

$100 a day, you don't honestly believe Forest will only charge $100 when they over bid for a drug by close to $300 million. Take a look back at the history of this product and see what financial people said "might not ever have a positive return on investment". This on top of severe resistance within the 1st 1-2yrs, good luck with this. All you will do is make more noise in the market which will get all other products used more, so thanks!
 
$100 a day, you don't honestly believe Forest will only charge $100 when they over bid for a drug by close to $300 million. Take a look back at the history of this product and see what financial people said "might not ever have a positive return on investment". This on top of severe resistance within the 1st 1-2yrs, good luck with this. All you will do is make more noise in the market which will get all other products used more, so thanks!

Many analysts projecting it to sell$400 million by 2014. Forest can put a lot of $ and manpower behind launch and they have a good presence in the managed care arena. It will have an impact and it will be a player. If you are afraid of competition go work in the post office. Don't make yahoo and make yourself look foolish.
 
$100 a day, you don't honestly believe Forest will only charge $100 when they over bid for a drug by close to $300 million. Take a look back at the history of this product and see what financial people said "might not ever have a positive return on investment". This on top of severe resistance within the 1st 1-2yrs, good luck with this. All you will do is make more noise in the market which will get all other products used more, so thanks!

Actually, if Forest expects this drug to be any kind of player (ie: empiric use) they will have to price it in the 50-60 dollar range. Hospitals don't care about convenience more than they care about cost, and generic cefepime + vanc., or generic Rocephin + vanc. acquisition cost is less than $50 p/day. You notice I said acquisition cost of vanc. The true cost of vanc. is irrelevant, as anyone in this business knows, because pharmacy is judged only on acquisition cost of a drug. The latest finacial estimate I read today is the drug is expected to reach 300 mill in sales, but no timeline was given. Granted, gram - resistance will decrease the utility of this drug, but it will be a player if priced right, at least for the short term. And doctors are comfortable with ceph's as a drug class. I just don't think that Forest has a clue about the hospital antibiotic market. From what I've seen, they don't even have a clue about hiring for their hospital positions. Inexperienced managers and reps. = cluster____.
 
Once I found out that the NJ DM was a recently promoted Forest PC rep, without any DM experience, hospital experience, injectible experience, or antibiotic experience. I told the hiring DM that he is in over his head, and he could work for me but I could not work for him. I then told him that only the desperate out of work rep would look at this opportunity and be excited. No thanks. Nothing to worry about here in NJ.
 
FOREST IS GIVING CUBIST THE BIGGEST CHRISTMAS GIFT EVER.

THEY ARE HAVING REPS WITH NO PRIOR ACUTE HOSPITAL SALES EXPERIENCE. ACTUALLY SCARY... THEY ARE HAVING LTC REPS AND PC REPS TO DO THE JOB OF LAUNCHING THIS PRODUCT. MANAGEMENT WITH NO ACUTE HOSPITAL INJECTABLE OR IV EXPERIENCE. SCARY!!!!

NO RELATIONSHIPS IN ID, ED AND ICU. DO NOT HAVE THE EXPERIENCE OR KNOWLEDGE TO GET THROUGH P&T PROCESS.

THEY ARE NO THREAT! NO EXPERIENCE BUT MANAGEMENT THINKS IT WILL BE SO EASY TO GAIN ACCESS IN THE INSTITUTIONS.

IGNORANCE IS BLISS!!!! THEY PLAN ON PRICING THE MED AROUND 70-80.00

GOOD LUCK FOREST !!!! THEY NEED LUCK! CUBIST WILL STILL BE THE BEST!!!
 
Keep thinking we are fools, Cubist. Grow Up.
We'll have contracts pushing our sad little drug onto every hospital formulary within the first 6 months of launch. How's your hospital team? Managed Care Team? CSL's? Trade? Marketing? What, do you one person for all those jobs?

You think this is our first product launch? We might have had some success with this sort of thing in the past... just maybe?

FYI, we will be better then the Vanco sales force that has been kicking your butt since your launch. Oh wait, Vanco doesn't have a sales force. Right.

You guys keep raising your price and please keep that steady flow of new compelling data coming out. 7 years of data and what's that market share again?

That is the gift that will keep on giving!!!!

You guys are awesome, keep promoting from within, that's where all the talent is.
 


Write your reply...